Disc Medicine, Inc. (NASDAQ:IRON) Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC lifted its position in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 69.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,890 shares of the company’s stock after buying an additional 3,243 shares during the period. Intech Investment Management LLC’s holdings in Disc Medicine were worth $500,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its stake in Disc Medicine by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company’s stock worth $400,000 after acquiring an additional 593 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Disc Medicine by 2.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,065 shares of the company’s stock worth $1,428,000 after purchasing an additional 771 shares during the last quarter. Rhumbline Advisers raised its holdings in Disc Medicine by 5.7% in the 4th quarter. Rhumbline Advisers now owns 29,036 shares of the company’s stock valued at $1,841,000 after buying an additional 1,553 shares during the period. MetLife Investment Management LLC lifted its position in Disc Medicine by 18.0% in the third quarter. MetLife Investment Management LLC now owns 11,377 shares of the company’s stock valued at $559,000 after buying an additional 1,735 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Disc Medicine by 16.1% during the third quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company’s stock valued at $799,000 after acquiring an additional 2,257 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on IRON shares. Stifel Nicolaus increased their price objective on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. Cantor Fitzgerald lifted their price objective on Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, March 18th. TD Cowen assumed coverage on Disc Medicine in a report on Thursday, February 27th. They set a “buy” rating for the company. Scotiabank boosted their price target on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, March 3rd. Finally, Morgan Stanley reissued an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a research note on Friday, March 7th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $93.80.

Disc Medicine Trading Up 2.8 %

Shares of NASDAQ:IRON opened at $53.70 on Tuesday. The company has a market cap of $1.86 billion, a PE ratio of -13.49 and a beta of 0.73. The company’s 50 day moving average is $55.16 and its two-hundred day moving average is $56.13. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $68.73.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.08. As a group, equities research analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Insider Buying and Selling

In other Disc Medicine news, Director Mona Ashiya sold 10,011 shares of the firm’s stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $54.00, for a total transaction of $540,594.00. Following the sale, the director now owns 187,297 shares of the company’s stock, valued at approximately $10,114,038. This trade represents a 5.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John D. Quisel sold 13,012 shares of the company’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $61.95, for a total transaction of $806,093.40. Following the completion of the transaction, the chief executive officer now owns 72,065 shares of the company’s stock, valued at approximately $4,464,426.75. The trade was a 15.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 376,464 shares of company stock worth $20,614,329 over the last 90 days. 4.24% of the stock is owned by insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.